Previous 10 | Next 10 |
2024-03-27 17:08:02 ET Using psychedelic molecules to address mental health disorders Cybin Inc.'s primary focus is to take classical psychedelic molecules and transform them into useful therapeutic agents for mental health disorders. "We have a global issue and inadequate tre...
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ...
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, will be presenting at this week’s Public Ventures Discovery Day. Th...
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, toda...
2024-03-15 10:24:53 ET More on Cybin De-Risking Psychedelics: Compass Pathways, Cybin And Atai Cybin to begin Phase 3 study for psychedelic drug mid-year Cybin launches $150M oversubscribed private placement Seeking Alpha’s Quant Rating on Cybin ...
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is reporting the initiation of a Phase 2 proof-of-concept study of CYB004, its pr...
- Anxiety disorders are the most prevalent mental health disorders globally 1 , contributing to over 28 million disability-adjusted life years (“DALYs”) 2 - - Highly scalable intermittent treatment for Generalized Anxiety Disorder (“GAD”) with an expect...
2024-03-14 12:52:06 ET More on Cybin De-Risking Psychedelics: Compass Pathways, Cybin And Atai Cybin launches $150M oversubscribed private placement Cybin spikes after FDA breakthrough tag for psychedelic therapy Seeking Alpha’s Quant Rating on Cybin ...
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, is reporting on its end-of-phase-2 meeting with the U.S. Food and Drug Adm...
- With U.S. Food and Drug Administration (“FDA”) alignment on multisite, multinational Phase 3 program design Company expects to commence Phase 3 program around mid-year 2024 - - 15 U.S. clinical trials sites targeted; European sites to be added - - Robust and sustai...
News, Short Squeeze, Breakout and More Instantly...
Cybin Inc. Company Name:
CYBN Stock Symbol:
NYSE Market:
Cybin (NYSE American: CYBN) (Cboe CA: CYBN) , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation, psychedelic-based treatment options, will be participating in an upcoming virtual Alliance Global Partners Heal...
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“ Cybin ” or the “ Company ”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, is pleased...
Florida-based cannabis company Kaya Holdings Inc ., AKA KAYS, (OTCQB:KAYS) has been awarded a license by the Oregon Health Authority to operate ...